Latest news with #Salva
Time of India
03-06-2025
- Entertainment
- Time of India
A Widow's Game ending explained: How Maje and Salva were finally exposed
A Widow's Game ending explained: Released on Netflix, A Widow's Game has become one of the most popular films on the platform. The movie is based on the true story of a woman involved in her husband's murder, who lives a secret life and entangles everyone in a web of a thousand lies. The film has left viewers shocked, and if you've watched it and want to understand more about how it ends, we've got you covered. Let's dive in. (Spoilers ahead, you know what to do) A Widow's Game ending explained Before we dive into how the film ends, let's have a little backgrounder. So, the woman Maje referred to as the widow in the movie tries desperately to cover up what she did. What she did was, along with her lover Salva, plan the murder of her husband. But it isn't that simple. The woman who kept spinning stories was, in fact, living a double life herself, involved in multiple affairs while still married. With each new affair, she managed to invent new lies to maintain her facade. Now that you know a bit of the background, let's take a look at how the movie ended. Why did Maje want to kill her husband? Well, Maje and her husband were two very different people. While Arturo was a family man, Maje wanted more from life. Let's just say she craved excitement and thrill, and being with Arturo didn't fulfill her in any way. That's why she went on to have multiple affairs and eventually planned to kill her husband with her lover, Salva. How were Maje and Salva caught? The investigators had been tapping Maje and Salva's phones for a while, and they eventually recorded conversations that confirmed their suspicions. The police also planted a microphone inside a tissue box during one of Maje and Salva's meetings, which further proved their guilt. Both were arrested, and as previously agreed, Maje denied any involvement in the murder while Salva took full responsibility. However, Salva later revealed that Maje had manipulated him into committing the crime. As a result, Maje was sentenced to 22 years in prison, while Salva received 17 years. You can stream A Widow's Game on Netflix.
Yahoo
13-05-2025
- Business
- Yahoo
Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates
BRANFORD, Conn., May 13, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the quarter ended March 31, 2025, and provided a business update. Q1 2025 and Recent Business Highlights Announced acceptance of poster detailing the Phase 1/2 clinical trial of the ATR-04 program in EGFR inhibitor ("EGFRi")-associated rash at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting Entered into Purchase Agreement for up to $20 Million in Partnership with institutional investor Alumni Capital LP, to fund clinical pipeline Announced closing of two public offerings raising a total of $2.2M "The start of 2025 has been a vital period for Azitra as we build towards key milestones expected by mid-year for our first-in-class, precision, live biotherapeutic candidates designed for major undertreated dermatological diseases," said Francisco Salva, CEO of Azitra. "For ATR-12, our lead program targeting the rare, chronic and devastating Netherton syndrome, we expect to provide initial safety data from our Phase 1b trial in the first half of 2025 with topline results expected by year-end 2025. There are no approved treatments for Netherton syndrome, and we believe this novel approach has potential to be life-changing for these patients." Salva continued: "Also by mid-2025, we look forward to dosing the first patient in our Phase 1/2 trial with our ATR-04 program, which contains a live biotherapeutic product candidate containing an isolated, naturally derived S. epidermidis strain being developed for the treatment of EGFRi-associated rash. EGFRi-associated rash is a dermatologic toxicity that often accompanies EGFRi treatments for cancer, impacting approximately 150,000 patients in the United States annually. These severe skin conditions can interfere with cancer treatment efforts, often causing significant physical and psychological discomfort for patients. Given the importance of EGFRi therapies to the cancer industry, Azitra was invited to present an update of our ATR-04 Phase 1/2 trial at ASCO 2025, which is the most prestigious cancer research conference in the world." Salva concluded: "The remainder of 2025 is expected to be a milestone-rich period for Azitra during which we look forward to showcasing the potential of ATR-12 and ATR-04, as well as our unique, proprietary platform for delivering engineered proteins using topical live biotherapeutic products." Pipeline and Anticipated Milestones 1H 2025: Initial safety data from first set of Netherton syndrome patients in the ATR-12 Phase 1b trial 1H 2025: First patient dosed with for EGFRi-associated rash in a Phase 1/2 trial for ATR-04 YE 2025: Topline data of the Phase 1b trial with ATR-12 in Netherton syndrome patients Financial Results for the Quarter Ended March 31, 2025 Research and Development (R&D) expenses: R&D expenses for the quarter ended March 31, 2025, were $1.3 million compared to $1.5 million for the comparable period in 2024. General and Administrative (G&A) expenses: G&A expenses for the quarter ended March 31, 2025, were $1.9 million compared to $1.5 million for the comparable period in 2024. Net Loss was $3.1 million for the quarter ended March 31, 2025, compared to $2.9 million for the comparable period in 2024. Cash and cash equivalents: As of March 31, 2025, the Company had cash and cash equivalents of $3.2 million. About Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology. The Company's lead program, ATR-12, uses an engineered strain of S. epidermidis designed to treat Netherton syndrome, a rare, chronic skin disease with no approved treatment options. Netherton syndrome may be fatal in infancy with those living beyond a year having profound lifelong challenges. The ATR-12 program includes a Phase 1b clinical trial in adult Netherton syndrome patients. ATR-04, Azitra's additional advanced program, utilizes another engineered strain of S. epidermidis for the treatment of EGFR inhibitor ("EGFRi") associated rash. Azitra has received Fast Track designation from the FDA for EGFRi associated rash, which impacts approximately 150,000 people in the U.S. Azitra has an open IND for its ATR-04 program in patients with EGFRi associated rash. The ATR-12 and ATR-04 programs were developed from Azitra's proprietary platform of engineered proteins and topical live biotherapeutic products that includes a microbial library comprised of approximately 1,500 bacterial strains. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen the library of strains for drug like molecules. For more information, please visit Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding the expected timing of (i) our provision of initial safety data and topline results for the phase 1b trial for our ATR-12, (ii) the abstract detailing the Phase 1/2 clinical trial for our ATR-04 program and (iii), the initiation of dosing in the Phase 1/2 clinical trial for our ATR-04 program, and statements about our clinical and preclinical programs, and corporate and clinical/preclinical strategies. Any forward-looking statements in this press release are based on current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to that we may experience delays in the provision of initial safety data and topline results for ATR-12 or, if we do, that such data may not be favorably received, we may fail to present this abstract detailing the Phase 1/2 clinical trial or, if we are able to do so, that the abstract will be favorably received; we may experience delays in the dosing the first patient in this Phase 1/2 trial; our product candidates may not be effective; there may be delays in regulatory approval or changes in regulatory framework that are out of our control; our estimation of addressable markets of our product candidates may be inaccurate; we may fail to timely raise additional required funding; more efficient competitors or more effective competing treatment may emerge; we may be involved in disputes surrounding the use of our intellectual property crucial to our success; we may not be able to attract and retain key employees and qualified personnel; earlier study results may not be predictive of later stage study outcomes; and we are dependent on third-parties for some or all aspects of our product manufacturing, research and preclinical and clinical testing. Additional risks concerning Azitra's programs and operations are described or incorporated by reference in our annual report on Form 10-K filed with the SEC on February 24, 2025. Azitra explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact Norman StaskeyChief Financial Officerstaskey@ Investor Relations Tiberend Strategic Advisors, Nugent205-566-3026jnugent@ Media Relations Tiberend Strategic Advisors, McDonald 646-577-8520cmcdonald@ Condensed Statement of Operations(Unaudited) Three months Ended March 31,2025 2024Operating expenses: General and administrative$ 1,850,138 $ 1,488,527Research and development 1,250,1001,472,970Total operating expenses 3,100,2382,961,497 Loss from operations (3,100,238)(2,961,497) Other income (expense): Interest income 37,1647,609Interest expense (1,293)(915)Change in fair value of warrants 14328,255Other expense (4,121)(6,327)Total other income 31,89328,622) Net loss before income taxes (3,068,345)(2,932,875) Income tax expense -- Net loss$ (3,068,345) $ (2,932,875)Net loss attributable to common shareholders$ (3,068,345)(2,932,875)Net loss per Share, basic and diluted$ (0.23) $ (4.32)Weighted average common stock outstanding, basic and diluted 13,171,516678,885 Condensed Balance Sheets(Unaudited) March 31, December 31,2025 2024Assets Current Assets: Cash and cash equivalents$ 3,206,710 $ 4,554,719Other receivables 103,046101,896Prepaid expenses and other current assets 561,798571,675Total current assets$ 3,871,554 $ 5,228,290 Property and equipment, net 621,012653,957Other assets 1,415,3251,476,555Total assets$ 5,907,891 $ 7,358,802 Liabilities, and stockholders' equity Current liabilities: Accounts payable$ 558,924 $ 490,255Current financing lease liability 16,45616,066Current operating lease liability 237,647255,177Accrued expenses 467,394614,359Total current liabilities 1,280,4211,375,857Long-term financing lease liability 5,84310,105Long-term operating lease liability 213,765274,161Warrant liability 238381Total liabilities 1,500,2671,660,504Stockholders' equity Common stock 1,498763Additional paid-in capital 65,040,29663,263,360Accumulated deficit (60,634,170)(57,565,825)Total stockholders' equity 4,407,6245,698,298Total liabilities and stockholders' equity$ 5,907,891 $ 7,358,802 View original content to download multimedia: SOURCE Azitra, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Buzz Feed
12-03-2025
- Entertainment
- Buzz Feed
What's A Really Awful Scandal Hollywood Just Casually Forgot About But You Can Never Forget?
Tragedies and scandals happen in Hollywood more often than studios, producers, and the media would like to admit. And often, these stories get brushed under the rug, remembered by only a maybe that's you! Warning: Mentions of child molestation, rape, and other dark subject matter ahead. For example, maybe you CANNOT believe people never talk about the fact that Jeepers Creepers writer-director Victor Salva is a convicted child molester and rapist who was able to continue making films, even for Disney, even after his conviction. According to IndieWire, "The 59-year-old was convicted in 1988 of the sexual molestation of Nathan Forrest, the 12-year-old actor and star of his film Clownhouse. Salva videotaped the sexual act and was also convicted of possessing commercial videotapes and magazines containing child pornography. Salva only served 15 months of his three-year sentence, and he somehow went on to have a career in Hollywood in the years that followed. Disney hired him to direct their supernatural drama Powder, and Salva found his greatest success with Jeepers Creepers the 2001 horror film that spawned a franchise." Or maybe you can't believe more people don't know about the tragic story of Gabriella Cedillo, an extra on the film Transformers: Dark of the Moon (2011). She sustained permanent brain damage after the car she was driving for a scene involving a stunt was hit by a large piece of metal. Chicago Tribune / Tribune News Service via Getty Images According to ABC7: "Gabriela Cedillo was just finishing college in September 2010 when the car she was driving in a Transformers 3 scene was struck by a piece of metal. It was attached to a tow cable to flip a stunt car in the westbound lanes of Cline Avenue in Hammond. Instead, the metal bar broke free, and it smashed through her windshield into the right side of her head." In 2012, Cedillo received an $18.5 million settlement from the film's producers. Or, perhaps, you'll never forget the fact that Kenneth Branagh cheated on then-wife Emma Thompson with Helena Bonham Carter in 1995. Georges De Keerle / Getty Images According to the Independent, "After two years of dating, Thompson and Branagh married on Aug. 20, 1989. [...] The relationship didn't last, and the couple ultimately announced their separation in 1995. It was later revealed that Branagh was having an affair with Helena Bonham Carter." "Thompson would go on to tell the New Yorker that the real reason for the divorce was her discovery that Branagh had started a relationship with Bonham Carter, who was starring in his film Mary Shelley's Frankenstein. "I was utterly, utterly blind to the fact that he had relationships with other women on set," she told the outlet. "What I learned was how easy it is to be blinded by your own desire to deceive yourself.'" So, tell us, what's a shocking, dark, or wild Hollywood scandal that truly got swept under the rug — one that people seem to have forgotten about? Tell us in the comments below or via this anonymous form and you could be featured in an upcoming BuzzFeed Community
Yahoo
25-02-2025
- Business
- Yahoo
Google Makes Gemini Code Assistant Available for Everyone
Google is throwing a major lifeline to students and hobbyist coders with Gemini Code Assistant, a free AI coding assistant that supports all publicly available coding languages, the company said Tuesday. Gemini Code Assistant, previously available only for enterprise customers, will give everyone access to a "practically unlimited" AI coding assistant, the company said in a press release. Gemini Code Assistant allows 180,000 completions per month, which Google says is 90 times more code completions than other free coding assistants on the market. "A professional developer coding every day is probably going to use maybe half of that," said Ryan J. Salva, senior director of product at Google in charge of developer experiences. "You would have to be a wildly dedicated developer coding 14 hours a day, every day, just banging on it in order to get to those limits." Google says Gemini Code Assistant has a generous 128,000 input token support in chat and can use natural language to help generate, explain or improve code. For example, you could ask Gemini to write a script that sends a daily email with the latest weather forecast and get workable code. Code Assistant, however, isn't at the level where a novice can simply give Gemini Code Assistant a prompt and develop a fully fledged program. Salva sees 2025 as the year when AI helps coders not only produce more code but better-quality code. Within software teams, it's common for developers to go through code review, in which their code is overlooked by a supervisor who then gives them tips on how to improve. Salva says AI agents within Gemini can help with this, freeing up more time for developers. Google also will have a public preview of Gemini Code Assist for GitHub. "We've built an AI agent that performs the work of a teammate or a co-worker who reviews the code contributed for defects," Salva said, "looking for, 'are you following best practices?' [or] 'Are there ways to make the logic more elegant?'" Google's release of Gemini Code Assistant comes as Big Tech is quickly trying to mark areas of AI dominance. Right now, ChatGPT is considered the default for AI-assisted chatbots, with 400 million weekly users. Some of ChatGPT's success has to do with its viral launch in late 2022. There's tremendous power in being considered the default piece of technology. By making Code Assistant freely available, Salva says the business case is to help drive lifelong adoption of Google's AI services. Business cases aside, Salva sees Gemini Code Assistant as a major step in helping people begin making programs in natural language, where little coding knowledge is required. "The large language models can do the work of writing the independent logic for you," Salva said. "And this makes humans a lot more creative... it increases their creative output because they no longer have that language barrier."
